Urogenital Cancers: Diagnostic, Predictive, and Prognostic Markers

Guest Editor:

Dr. Makito Miyake
Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan

Deadline for manuscript submissions:
closed (30 November 2019)

Message from the Guest Editor

Dear Colleagues,

Urogenital cancers include urothelial cancer, renal cell carcinoma, prostate cancer, testicular cancer, and other types of malignancies arising from retroperitoneal organs. There are still unsolved problems in early diagnosis, treatment selection, and precision medicine in this field. The forthcoming Special Issue will welcome submissions on, but not limited to, the following topics:

- Morbidity risk factors
- Non-invasive detection biomarkers (focusing on early detection is preferred)
- Novel DNA, RNA, protein biomarkers
- Novel systemic inflammation markers and nutritional markers such as the NLR, CRP, and GPS
- Novel radiographic markers
- Histological variants and their clinical impact
- Predictors of treatment responses
- Precision medicine
- Immunotherapy including immune check point inhibitors
- Decreasing morbidity risk, recurrence risk, and progression risk
- Upstaging in surgical specimens: gap between clinical stage and pathological stage
- Interpretation of cancer screening trials such as PSA screening in prostate cancer and urianalysis screening for bladder cancer

Dr. Makito Miyake
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*)

Contact Us